OOIR: Observatory of International Research

Papers

(The H4-Index of European Journal of Immunology is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)	252
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset	180
Divergent SARS‐CoV‐2‐specific T‐ and B‐cell responses in severe but not mild COVID‐19 patients	108
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action	98
Human NK cells, their receptors and function	96
Natural killer cell engagers in cancer immunotherapy: Next generation of immuno‐oncology treatments	94
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy	82
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans	67
Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction	66
Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15	64
Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway	62
The expanding world of tissue‐resident macrophages	60
Treg cell therapy: How cell heterogeneity can make the difference	58
JAK inhibitors: Ten years after	58
Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease	57
CD8⁺ Tregs revisited: A heterogeneous population with different phenotypes and properties	53
Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients	51
High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris	50
Complement cascade in severe forms of COVID‐19: Recent advances in therapy	47
Helios is a marker, not a driver, of human Treg stability	46
CAR T cells: Building on the CD19 paradigm	45
Peptide microarray‐based analysis of antibody responses to SARS‐CoV‐2 identifies unique epitopes with potential for diagnostic test development	44
Natural killer cell‐mediated ADCC in SARS‐CoV‐2‐infected individuals and vaccine recipients	43
Neutrophil activation and neutrophil extracellular traps (NETs) in COVID‐19 ARDS and immunothrombosis	41
Crossing the barriers: Revisiting the gut feeling in rheumatoid arthritis	40

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy	40
Innate immune inflammatory cell death: PANoptosis and PANoptosomes in host defense and disease	40
Metabolic reprograming shapes neutrophil functions in severe COVID‐19	39
Differential Interleukin‐8 thresholds for chemotaxis and netosis in human neutrophils	39
Altered increase in STAT1 expression and phosphorylation in severe COVID‐19	39
Regulatory T‐cell development in the tumor microenvironment	37
Anti‐heart antibodies levels and their correlation with clinical symptoms and outcomes in patients with confirmed or suspected diagnosis COVID‐19	36
Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α	36
The role of the gut microbiota and microbial metabolites in neuroinflammation	36
IL‐17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation toward bone‐forming cells in ankylosing spondylitis	35